{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:40:09Z","timestamp":1791276009306,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>We studied 63 patients with myasthenia gravis (MG) requiring treatment with intravenous immunoglobulin, to determine if polymorphisms within the FC\u03b3R2A (rs1801274), FC\u03b3R2B (rs1050501), FC\u03b3R3A (rs396991), and FC\u03b3R3B (NA1\/NA2) genes are correlated with response to treatment. There was no significant difference in any of the polymorphisms studied between responders and nonresponders. Patients with the FC\u03b3R2B-232I\/I polymorphism had higher disease severity measured by the quatitative myasthenia gravis score (QMGS). There was no difference in the distribution of the FC\u03b3R2B-232 polymorphisms between the patients and 90 healthy controls. The finding of greater disease severity in patients with the FC\u03b3R2B-232I\/I polymorphism requires confirmation in a larger population of patients with myasthenia gravis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0b013e31825c566b","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T07:35:08Z","timestamp":1345793708000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Fc\u03b3 Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis"],"prefix":"10.1097","volume":"14","author":[{"given":"Carolina","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakob","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Rogaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Katzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"St George-Hyslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-1-20240808","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"R5-1-20240808","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":". Comparison of IVIg and PLEX in patients with myasthenia gravis.","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"R6-1-20240808","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":". Intravenous immunoglobulinsunderstanding properties and mechanisms.","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"R7-1-20240808","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":". Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.","volume":"342","author":"Debre","year":"1993","journal-title":"Lancet"},{"key":"R8-1-20240808","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-3476(86)80691-6","article-title":"Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations.","volume":"109","author":"Burdach","year":"1986","journal-title":"J Pediatr"},{"key":"R9-1-20240808","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":". Intravenous immune globulin (10 caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"R10-1-20240808","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","article-title":". High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study.","volume":"40","author":"van Doorn","year":"1990","journal-title":"Neurology"},{"key":"R11-1-20240808","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":". Impaired inhibitory Fc receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-1-20240808","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jneuroim.2006.01.015","article-title":". Genetic evidence for the involvement of Fc receptor III in experimental autoimmune myasthenia gravis pathogenesis.","volume":"174","author":"Tuzun","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R13-1-20240808","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s002510050426","article-title":"V de WJ. IgG receptor polymorphisms: risk factors for disease.","volume":"48","author":"van der Pol","year":"1998","journal-title":"Immunogenetics"},{"key":"R14-1-20240808","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneuroim.2003.08.043","article-title":". Association of the Fc receptor IIA-RR131 genotype with myasthenia gravis in Dutch patients.","volume":"144","author":"van der Pol","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R15-1-20240808","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(97)00174-4","article-title":". FcRIIA and FcRIIIB polymorphisms in myasthenia gravis.","volume":"81","author":"Raknes","year":"1998","journal-title":"J Neuroimmunol"},{"key":"R16-1-20240808","first-page":"198","article-title":". Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J"},{"key":"R17-1-20240808","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2010.136283","article-title":". Fc receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.","volume":"70","author":"Okuyama","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R18-1-20240808","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1067\/mai.2003.1380","article-title":"IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy.","volume":"111","author":"Binstadt","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"R19-1-20240808","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10875-005-4697-7","article-title":". Polymorphism of Fc RIIa may affect the efficacy of -globulin therapy in Kawasaki disease.","volume":"25","author":"Taniuchi","year":"2005","journal-title":"J Clin Immunol"},{"key":"R20-1-20240808","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcRIIB in autoimmunity and infection: evolutionary and therapeutic implications.","volume":"10","author":"Smith","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R21-1-20240808","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bioinformatics\/19.1.149","article-title":"Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.","volume":"19","author":"Purcell","year":"2003","journal-title":"Bioinformatics"},{"key":"R22-1-20240808","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/art.20151","article-title":". Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish population.","volume":"50","author":"Magnusson","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201209000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:24:56Z","timestamp":1723159496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201209000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e31825c566b","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}